Vicor's Q3 results validate AI-driven growth and royalty durability, but valuation risk persists amid 4.5% share gain.

What happened

Vicor reported Q3 earnings that jumped 111.1% and revenues that surged 78.5% year-over-year, driven by strong AI demand, soaring royalty income, and robust Advanced Products sales, sending shares up 4.5%. These results align with the bull case outlined in the latest DeepValue report, which required quarterly royalties above $25 million and continued revenue growth to support the thesis. The previous WAIT rating was based on the need for proof of royalty durability and backlog conversion, and this quarter provides that evidence, though the press release lacks details on backlog and Fab 2 timing. The stock's positive reaction suggests the market is rewarding execution, but the rally also pushes the valuation higher, potentially reducing the margin of safety. Investors should await the full 10-Q to confirm royalty trends and any updates on capacity expansion before revising positions.

Implication

The strong Q3 results validate the royalty and AI-demand thesis, reducing downside risk, but the stock's 4.5% gain likely pushes it above the previous trim level of $260, signaling limited upside at current prices. Existing holders should maintain positions given the positive fundamental trajectory, but new money should be patient and look for a retracement toward the $225 base-case implied value. Key risks remain the lack of a committed Fab 2 timetable and the potential for royalty revenue to normalize if customer usage slows. If the 10-Q confirms royalties above $25 million and backlog above $350 million with a capacity plan, the thesis strengthens further, and a higher valuation may be justified. Conversely, any sign of royalty lumpiness or supply-chain constraints would warrant reducing exposure.

Thesis delta

The thesis shifts from 'show me' to 'confirmed' on the revenue and royalty fronts, as Q3 outperformance validates the core demand drivers. However, the lack of details on backlog and Fab 2 leaves the capacity constraint risk unresolved, and the post-earnings rally likely prices in much of the good news. The rating remains WAIT with a slightly higher conviction, but the attractive entry level may need to be revised upward if the stock consolidates above $250.